Association between pioglitazone use and head and neck cancer: Population-based case-control study

Tzong-Hann Yang; Sudha Xirasagar; Yen-Fu Cheng; Chuan-Song Wu; Yi-Wei Kao; Ben-Chang Shia; Herng-Ching Lin

doi:10.1002/hed.26046

Association between pioglitazone use and head and neck cancer: Population-based case-control study

Head Neck. 2020 Apr;42(4):653-659. doi: 10.1002/hed.26046. Epub 2019 Dec 13.

Authors

Tzong-Hann Yang^{1

2

3}, Sudha Xirasagar⁴, Yen-Fu Cheng^{2

5

6

7}, Chuan-Song Wu¹, Yi-Wei Kao^{8

9}, Ben-Chang Shia^{8

10

11}, Herng-Ching Lin^{12

13}

Affiliations

¹ Department of Otorhinolaryngology, Taipei City Hospital, Taipei, Taiwan.
² Department of Speech, Language and Audiology, National Taipei University of Nursing and Health, Taipei, Taiwan.
³ Research Center of Sleep Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
⁴ Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina.
⁵ Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.
⁶ Department of Otolaryngology-Head and Neck Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.
⁷ Department of Otolaryngology-Head and Neck Surgery, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
⁸ Big Data Research Center, Taipei Medical University, Taipei, Taiwan.
⁹ Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, New Taipei City, Taiwan.
¹⁰ College of Management, Taipei Medical University, Taipei, Taiwan.
¹¹ Executive Master Program of Business Administration in Biotechnology, College of Management, Taipei Medical University, Taipei, Taiwan.
¹² Sleep Research Center, Taipei Medical University Hospital, Taipei, Taiwan.
¹³ School of Health Care Administration, College of Management, Taipei Medical University, Taipei, Taiwan.

PMID: 31833151
DOI: 10.1002/hed.26046

Abstract

Background: This study aimed to evaluate the association between pioglitazone use and the occurrence of head and neck cancer.

Methods: Data for this case-control study were retrieved from the Taiwan National Health Insurance Research Database. A total of 21 464 diabetic patients newly diagnosed with head and neck cancers were identified. We used propensity score matching to select 64 392 comparison patients (3:1 ratio). Multiple logistic regression modeling was used to examine the association of head and neck cancer with pioglitazone use in the 5 years preceding the cancer diagnosis.

Results: Bivariate analysis showed a significant difference in the prevalence of prior using pioglitazone between cases and controls (19.3% vs 18.5%, P < .001) was observed. Multiple regression analysis showed adjusted odds of pioglitazone use of 1.06 (95% CI: 1.02-1.10) among cases relative to controls.

Conclusions: Prior pioglitazone use was associated with oral cavity cancer.

Keywords: diabetes; epidemiology; head and neck cancer; oral cavity cancer; pioglitazone.

MeSH terms

Case-Control Studies
Head and Neck Neoplasms* / epidemiology
Humans
Hypoglycemic Agents* / adverse effects
Pioglitazone / therapeutic use
Taiwan / epidemiology

Substances

Hypoglycemic Agents
Pioglitazone